Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31322592 | 0.83 | CYP11B2 (0.35) | — | |
| SCHEMBL22198892 | 0.83 | BACE1 (0.35) | TACR1BACE1 | |
| SCHEMBL1437192 | 0.79 | TACR1 (0.30) | TACR1 | |
| SCHEMBL18924077 | 0.78 | DUT (0.32) | — | |
| SCHEMBL1438559 | 0.78 | IDO1 (0.44) | IDO1 | |
| SCHEMBL13008101 | 0.78 | IDO1 (0.32) | IDO1 | |
| SCHEMBL5882318 | 0.76 | ALDH1A1 (0.41) | IDO1 | |
| SCHEMBL19656380 | 0.76 | BACE1 (0.32) | BACE1 | |
| SCHEMBL31371185 | 0.76 | CALM1 (0.50) | IDO1BACE1 | |
| SCHEMBL502282 | 0.76 | USP14 (0.33) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155590-A1 | Conjugates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | SANOFI SA (FR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155590-A1 | Conjugates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | SANOFI SA (FR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155590-A1 | Conjugates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | SANOFI SA (FR) | 2014-06-05 | — | — | US | disclosed |
| EP-2470547-B1 | CONJUGATES OF PYRROLO[1,4]BENZODIAZEPINE DIMERS AS ANTICANCER AGENTS | SANOFI SA (FR) | 2014-05-14 | — | — | EP | disclosed |
| US-8481042-B2 | Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents | SANOFI (FR) | 2013-07-09 | — | — | US | disclosed |
| US-8481042-B2 | Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents | SANOFI (FR) | 2013-07-09 | — | — | US | disclosed |
| US-8481042-B2 | Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents | SANOFI (FR) | 2013-07-09 | — | — | US | disclosed |
| US-20120244172-A1 | Conjudates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120244172-A1 | Conjudates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| EP-2470547-A1 | CONJUGATES OF PYRROLO[1,4]BENZODIAZEPINE DIMERS AS ANTICANCER AGENTS | SANOFI (FR) | 2012-07-04 | — | — | EP | disclosed |
| WO-2011023883-A1 | CONJUGATES OF PYRROLO[1,4]BENZODIAZEPINE DIMERS AS ANTICANCER AGENTS | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244172-A1 | Conjudates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | GABRA4, GABRA1, GABRA2 | TACR1 469/4885IDO1 970/4885BACE1 2466/4885 |
| US-20140155590-A1 | Conjugates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | GABRA4, GABRP, GABRA1 | TACR1 633/4885IDO1 1006/4885BACE1 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.